News & Analysis as of

Chemicals Pharmaceutical Industry

Goldberg Segalla

Will Industry Push Back Proactively on Potential PFAS-Use Restrictions?

Goldberg Segalla on

Over the past seven years, our blog has reported extensively on PFAS developments, litigation, and regulations — most of which has focused on the attention surrounding potential risks associated with PFAS, and the scrutiny...more

BakerHostetler

2024 BakerHostetler IP Perspectives - Forecasts, Trends and Accomplishments

BakerHostetler on

Trends, triumphs and challenges – the first annual BakerHostetler IP Perspectives (BHIPP) provides insights on all three fronts in the complex world of intellectual property (IP). From the potential hazards associated with...more

Society of Corporate Compliance and Ethics...

A look at the EU Market Surveillance Regulation

Report on Supply Chain Compliance 3, no. 21 (October 29, 2020) - The European Union has some of the world’s most robust environmental, health and safety standards for products sold and imported into the market. Despite...more

White & Case LLP

European leveraged finance: A bifurcated balancing act: Sector watch: Hot or not?

White & Case LLP on

HEADLINES - Industrials and chemicals in aggregate accounted for the largest share of loan activity (20 per cent) and high yield bonds (22 per cent) in Europe - Pharma, medical and biotech issuers were the second most...more

BCLP

French Competition Authority Ends 2017 With a Bang

BCLP on

The French Competition Authority (“FCA”) ended the year with two punitive decisions: in both cases, the parties were severely sanctioned for obstructionist behavior. In the first decision dated 20 December 2017, the FCA...more

Beveridge & Diamond PC

Latin American Environmental Regulatory Tracker

This month’s tracker reflects key initiatives from June16, 2017 – July 15, 2017. Latin America continues its breathtaking pace in releasing new environmental and sustainability initiatives and embracing international...more

Downs Rachlin Martin PLLC

News from the Vermont State House - An Analysis from DRM’s Government & Public Affairs Team - January 2017 #2

Treasurer Will Build Public Pension Plan for Small Business - State Treasurer Beth Pearce on Wednesday asked the Senate Economic Development, Housing and General Affairs Committee to create the framework for a...more

Hogan Lovells

French Legal and Regulatory Update – December 2016

Hogan Lovells on

The Paris office of Hogan Lovells is pleased to provide this English language edition of our monthly e-newsletter, which offers a legal and regulatory update covering France and Europe for December 2016. ...more

Bergeson & Campbell, P.C.

Wrap-Up of Federal and State Chemical Regulatory Developments, September 2015

EPA Releases TSCA Assessment Documents For Flame Retardant Chemicals: On August 18, 2014, the U.S. Environmental Protection Agency (EPA) released for public comment three Problem Formulation and Initial Assessment documents...more

Foley & Lardner LLP

Update on Mayo Myriad Patent Eligibility From USPTO BCP Partnership Meeting

Foley & Lardner LLP on

On September 17, 2015, the USPTO held the first “bicoastal” Biotechnology/Chemical/Pharmaceutical Customer Partnership meeting, with live participation from the USPTO’s main campus in Alexandria, VA and from San Jose...more

McDonnell Boehnen Hulbert & Berghoff LLP

Examination of Myriad-Mayo Guidance Comments -- ACLU

On March 4, the U.S. Patent and Trademark Office issued a guidance memorandum entitled "Guidance For Determining Subject Matter Eligibility Of Claims Reciting Or Involving Laws of Nature, Natural Phenomena, & Natural...more

Foley & Lardner LLP

Federal Circuit Finds Easy Solution to Avodart Solvate Written Description Question

Foley & Lardner LLP on

Are claims that recite a “solvate” of a chemical compound invalid for lack of written description if the patent does not describe any specific solvates? In GlaxoSmithKline LLC v. Banner Pharmacaps, Inc., the Federal Circuit...more

McDonnell Boehnen Hulbert & Berghoff LLP

GlaxoSmithKline LLC v. Banner Pharmacaps, Inc. (Fed. Cir. 2014)

The Federal Circuit issued an opinion on Monday in GlaxoSmithKline LLC v. Banner Pharmacaps, Inc. illustrating how difficult it can be to overturn a district court determination based on a question of fact, at least when the...more

Foley & Lardner LLP

The Danger of Self-Colliding Divisional Applications in the EPO

Foley & Lardner LLP on

Last week I had the honor of speaking at the 27th Annual Pharmaceutical/Chemical Patent Practice Update put on by the New Jersey Intellectual Property Law Association’s Chemical Practice Committee. The entire program was...more

14 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide